Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation

Hepatology

Volumn 61, Issue 3, 2015, Pages 895-904

  Nagai, Shunji ^a,b   Yoshida, Atsushi ^b   Facciuto, Marcelo ^a   Moonka, Dilip ^b   Abouljoud, Marwan S ^b   Schwartz, Myron E ^a   Florman, Sander S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; COLD ISCHEMIA; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIA; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MICROMETASTASIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STEROID THERAPY; TUMOR DIFFERENTIATION; BLOOD TRANSFUSION; CARCINOMA, HEPATOCELLULAR; COMPLICATION; LIVER; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; REPERFUSION INJURY; TIME; VASCULARIZATION;

BLOOD TRANSFUSION; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM RECURRENCE, LOCAL; REPERFUSION INJURY; TIME FACTORS;

EID: 84923288889     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27358     Document Type: Article

References (37)

1. Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, Freeman RB. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl 2011;17(Suppl 2):S81-S89.
2. Nagai S, Abouljoud MS, Kazimi M, Brown KA, Moonka D, Yoshida A. Peritransplant lymphopenia is a novel prognostic factor in recurrence of hepatocellular carcinoma after liver transplantation. Transplantation 2014;97:694-701.
3. Halazun KJ, Hardy MA, Rana AA, Woodland DC, Luyten EJ, Mahadev S, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009;250:141-151.
4. D'Amico F, Schwartz M, Vitale A, Tabrizian P, Roayaie S, Thung S, et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl 2009;15:1278-1287.
5. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
6. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-1403.
7. DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011;253:166-172.
8. Gouw AS, Balabaud C, Kusano H, Todo S, Ichida T, Kojiro M. Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl 2011;17(Suppl 2):S72-S80.
9. Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg 2011;254:108-113.
10. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
11. Man K, Ng KT, Lo CM, Ho JW, Sun BS, Sun CK, et al. Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases-activation of cell invasion and migration pathways. Liver Transpl 2007;13:1669-1677.
12. van der Bilt JD, Kranenburg O, Nijkamp MW, Smakman N, Veenendaal LM, Te Velde EA, et al. Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology 2005;42:165-175.
13. Ku Y, Kusunoki N, Shiotani M, Maeda I, Iwasaki T, Tominaga M, et al. Stimulation of haematogenous liver metastases by ischaemia-reperfusion in rats. Eur J Surg 1999;165:801-807.
14. Gray R. A class of K-sanple tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
15. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
16. Kaido T, Takada Y, Uemoto S. Usefulness of the Kyoto criteria as selection criteria for living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2010;16:538-540.
17. Piardi T, Gheza F, Ellero B, Woehl-Jaegle ML, Ntourakis D, Cantu M, et al. Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2012;19:2020-2026.
18. Llovet JM, Fuster J, Bruix J; Barcelona Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004;10(2 Suppl 1):S115-S120.
19. Kaido T, Takada Y, Uemoto S. Selection criteria for patients with hepatocellular carcinoma in liver transplantation. Transplantation 2009;88:442-443; author reply, 443.
20. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008;38:37-51.
21. Croome KP, Wall W, Chandok N, Beck G, Marotta P, Hernandez-Alejandro R. Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Liver Transpl 2013;19:1214-1223.
22. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999;5:221-225.
23. Axelson H, Fredlund E, Ovenberger M, Landberg G, Påhlman S. Hypoxia-induced dedifferentiation of tumor cells-a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 2005;16:554-563.
24. Brahimi-Horn C, Pouysségur J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 2006;93:E73-E80.
25. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-490.
26. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
27. Kaido T, Takada Y, Egawa H, Uemoto S. The influence of intraoperative homologous blood transfusion on prognosis after liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 2009;56:808-812.
28. Nagai S, Fujii T, Kodera Y, Kanda M, Sahin TT, Kanzaki A, et al. Impact of operative blood loss on survival in invasive ductal adenocarcinoma of the pancreas. Pancreas 2011;40:3-9.
29. Katz SC, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR, et al. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg 2009;249:617-623.
30. Ojima T, Iwahashi M, Nakamori M, Nakamura M, Naka T, Katsuda M, et al. Association of allogeneic blood transfusions and long-term survival of patients with gastric cancer after curative gastrectomy. J Gastrointest Surg 2009;13:1821-1830.
31. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006;(1):CD005033.
32. Lieberman MD, Shou J, Sigal RK, Yu J, Goldfine J, Daly JM. Transfusion-induced immunosuppression results in diminished host survival in a murine neuroblastoma model. J Surg Res 1990;48:498-503.
33. Ydy LR, Slhessarenko N, de Aguilar-Nascimento JE. Effect of perioperative allogeneic red blood cell transfusion on the immune-inflammatory response after colorectal cancer resection. World J Surg 2007;31:2044-2051.
34. Yamanaka N, Okamoto E, Fujihara S, Kato T, Fujimoto J, Oriyama T, et al. Do the tumor cells of hepatocellular carcinomas dislodge into the portal venous stream during hepatic resection? Cancer 1992;70:2263-2267.
35. Jubert AV, Lee ET, Hersh EM, McBride CM. Effects of surgery, anesthesia and intraoperative blood loss on immunocompetence. J Surg Res 1973;15:399-403.
36. Totsuka E, Fung JJ, Hakamada K, Ohashi M, Takahashi K, Nakai M, et al. Synergistic effect of cold and warm ischemia time on postoperative graft function and outcome in human liver transplantation. Transplant Proc 2004;36:1955-1958.
37. Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002;235:533-539.